Pleiotropic effects of statins: Benefit beyond cholesterol reduction?: A meta-regression analysis

Journal of the American College of Cardiology

Volumn 46, Issue 10, 2005, Pages 1855-1862

  Robinson, Jennifer G ^a,b   Smith, Brian ^a   Maheshwari, Nidhi ^a   Schrott, Helmut ^a  

^a UNIVERSITY OF IOWA   (United States)

^b SE226GH ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID SEQUESTRANT; COLESTIPOL; COLESTYRAMINE; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; POLYUNSATURATED FATTY ACID; PRAVASTATIN; SIMVASTATIN; SOYBEAN OIL;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CONTROLLED STUDY; CORONARY RISK; DEATH; DRUG EFFECT; EXPECTATION; HEART INFARCTION; HUMAN; ILEUM BYPASS; IMMUNOMODULATION; ISCHEMIC HEART DISEASE; LANGUAGE; LOW FAT DIET; MEDICAL INFORMATION; MEDLINE; OBSERVATION; PLEIOTROPY; PRIORITY JOURNAL; PUBLICATION; REGRESSION ANALYSIS; SAMPLE SIZE; SILENT MYOCARDIAL INFARCTION; STANDARDIZATION; TREATMENT OUTCOME;

CHOLESTEROL, LDL; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; REGRESSION ANALYSIS;

EID: 27644544308     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.05.085     Document Type: Article

References (94)

1. J. Davignon Beneficial cardiovascular pleiotropic effects of statins Circulation 109 Suppl 1 2004 III39 III43
2. S.E. Nissen High-dose statins in acute coronary syndromes not just lipid levels JAMA 292 2004 1365 1367
3. M. Aviram, M. Rosenblat, C. Bisgaier, R. Newton Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation Atherosclerosis 138 1998 271 280
4. D.T. Stein, S. Devaraj, D. Balis, B. Adams-Huet, I. Jialal Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia Arterioscler Thromb Vasc Biol 21 2001 2026 2031
5. B. Kwak, F. Mulhaupt, S. Myit, F. Mach Statins as a newly recognized type of immunomodulator Nat Med 6 2000 1399 1402
6. G. Weitz-Schmidt, K. Welzenbach, V. Brinkmann Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site Nat Med 7 2001 687 692
7. G.K. Sukhova, J.K. Williams, P. Libby Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol Arterioscler Thromb Vasc Biol 22 2002 1452 1458
8. F. Mach Statins as immunomodulatory agents Circulation 109 Suppl 1 2004 II15 II17
9. D. McCarey, I. McInnes, R. Mahdhok Trial of atorvastatin in rheumatoid arthritis (TARA) double-blind, randomised placebo-controlled trial Lancet 363 2004 2015 2021
10. U. Schonbeck, P. Libby Inflammation, immunity, and HMG-CoA reductase inhibitors statins as antiinflammatory agents? Circulation 109 Suppl 1 2004 II18 II26
11. L. Puccetti, A. Pasqui, M. Pastorelli Time-dependent effect of statins on platelet function in hypercholesterolemia Eur J Clin Invest 32 2002 901 908
12. B. Horvath, L. Szapary, Z. Marton, T. Alexy, G. Kesmarky, K. Toth Short-term effects of atorvastatin on haemorheologic parameters, platelet aggregation and endothelium dysfunction in patients with hypercholesterolaemia Eur Heart J 25 2004 96
13. U. Laufs, V. LaFata, J. Plutzky, J.K. Liao Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors Circulation 97 1998 1129 1135
14. R.P. Mason, M.F. Walter, R.F. Jacob Effects of HMG-CoA reductase inhibitors on endothelial function role of microdomains and oxidative stress Circulation 109 Suppl 1 2004 II34 II41
15. Y. Fukumoto, P. Libby, E. Rabkin Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits Circulation 103 2001 993 999
16. C.M. Ballantyne, M.A. Blazing, D.B. Hunninghake Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia results of the Comparative HDL Efficacy and Safety Study (CHESS) Am Heart J 146 2003 862 869
17. C.P. Cannon, E. Braunwald, C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
18. T. Fehr, C. Kahlert, W. Fierz Statin-induced immunomodulatory effects on human T cells in vivo Atherosclerosis 175 2004 83 90
19. E.J. Schaefer, J.R. McNamara, T. Tayler Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects Am J Cardiol 93 2004 31 39
20. J.C. LaRosa, S. Vupputuri Effect of statins on risk of coronary disease a meta-analysis of randomized, controlled trials JAMA 282 1999 2340 2346
21. T.J. Wilt, H.E. Bloomfield, R. MacDonald Effectiveness of statin therapy in adults with coronary heart disease Arch Intern Med 164 2004 1427 1436
22. G. Watts, B. Lewis, J. Brunt Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS) Lancet 339 1992 563 569
23. R. Knopp, C. Walden, B.M. Retzlaff Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men. The Dietary Alternatives Study JAMA 278 1997 1509 1515
24. W. Rogers, J. Canto, C. Lambrew Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999 the National Registry of Myocardial Infarction 1, 2 and 3 J Am Coll Cardiol 36 2000 2056 2063
25. American Heart Association Heart Disease and Stroke Statistics - 2004 Update 2004 American Heart Association Dallas, TX
26. J. Woodhill, A. Palmer, B. Leelathaepin, C. McGilchrist, R. Blacket Low fat, low cholesterol diet in secondary prevention of coronary heart disease Adv Exp Med Biol 109 1978 317 330
27. A. Dorr, K. Gundersen, J. Schneider Jr., T. Spencer, W. Martin Colestipol hydrochloride in hypercholesterolemic patients - effect on serum cholesterol and mortality J Chron Dis 31 1978 5 14
28. J. Brensike, R. Levy, S. Kelsey Effects of therapy with cholestyramine on progression of coronary atherosclerosis results of the NHLBI Type II Coronary Intervention Study Circulation 69 1984 313 324
29. Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease JAMA 251 1984 351 364
30. H. Buchwald, R. Varco, J. Matts Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) N Engl J Med 323 1990 946 955
31. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study Lancet 344 1994 1383 1389
32. J. Shepherd, S. Cobbe, I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
33. F.M. Sacks, M.A. Pfeffer, L. Moye Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction the Cholesterol And Recurrent Events trial (CARE) Am J Cardiol 68 1991 1436 1446
34. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
35. J.R. Downs, P.A. Beere, E. Whitney Design and rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Am J Cardiol 80 1997 287 293
36. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals a randomised placebo-controlled trial Lancet 360 2002 7 22
37. J. Shepherd, G.J. Blauw, M.B. Murphy The design of a prospective study of pravastatin in the elderly at risk (PROSPER) Am J Cardiol 84 1999 1192 1197
38. H. Holdass, B.C. Fellstrom, A.G. Jardine Effect of fluvastatin on cardiac outcomes in renal transplant recipients a multicentre, randomised, placebo-controlled trial Lancet 361 2003 2024 2031
39. P.S. Sever, B. Dahlof, N.R. Puolter Prevention of coronary and stroke events with atorvastatin in hypertensive patient who have average and lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA) a multicenter randomised controlled trial Lancet 361 2003 1149 1158
40. H. Calhoun, D. Betteridge, P. Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
41. Research Committee (From Three London Hospitals) Low-fat diet in myocardial infarction Lancet 2 1965 501 504
42. P. Leren The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction Acta Med Scand 466 1966 5 92
43. Report of a Research Committee to the Medical Research Council. Controlled trial of soya-bean oil in myocardial infarction Lancet 2 1968 693 699
44. S. Dayton, M. Pearce, S. Hashimoto, W. Dixon, U. Tomiyasu A controlled clinical trial of a diet high in unsaturated fat Circulation 40 Suppl II 1969 II1 II63
45. J. Downs, M. Clearfield, S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS JAMA 279 1998 1615 1622
46. T. Smith, D. Spiegelhalter, A. Thomas Bayesian approaches to random-effects meta-analysis a comparative study Stat Med 14 1995 2685 2699
47. S.N. Goodman Toward evidence-based medical statistics. 2 The Bayes factor Ann Intern Med 130 1999 1005 1013
48. G.A. Diamond, S. Kaul Prior convictions Bayesian approaches to the analysis and interpretation of clinical megatrials J Am Coll Cardiol 43 2004 1929 1939
49. WinBUGS Version 1.2 User Manual 1999 MRC Biostatistics Unit Cambridge
50. S. Chib Marginal likelihood from the Gibbs output J Am Stat Assoc 90 1995 1313 1321
51. S.M. Grundy, J.I. Cleeman, C.N.B. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
52. R. Bradford, C. Shear, A. Chremos Expanded clinical evaluation of lovastatin (EXCEL) study results Arch Int Med 151 1991 43 49
53. MAAS Investigators Effect of simvastatin on coronary atheroma the Multicentre Anti-Atheroma Study (MAAS) Lancet 344 1994 633 638
54. D.D. Waters, L. Higginson, P. Gladstone Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography the Canadian Coronary Atherosclerosis Intervention Trial Circulation 89 1994 959 968
55. C. Furberg, B. Pitt, R.P. Byington, J.-S. Park, M. McGovern PLAC-I and PLAC-II Investigators Reduction in coronary events during treatment with pravastatin Am J Cardiol 76 1995 60C 63C
56. J. Jukema, A. Bruschke, A. vanBoven Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels the Regression Growth Evaluation Statin Study (REGRESS) Circulation 91 1995 2528 2540
57. R. Salonen, K. Nyyssonen, E. Porkkala Kuopio Atherosclerosis Prevention Study (KAPS) a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries Circulation 92 1995 1758 1764
58. H. Bestehorn, U. Rensing, H. Roskamm The effect of simvastatin on progression of coronary artery disease. The multicenter Coronary Intervention Study (CIS) Eur Heart J 18 1997 226 234
59. A. Herd, C. Ballantyne, J. Farmer Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]) Am J Cardiol 80 1997 278 286
60. The Post Coronary Artery Bypass Graft Trial Investigators The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous vein coronary artery bypass grafts N Engl J Med 336 1997 153 162
61. K.K. Teo, J.R. Burton, C.E. Buller Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) Circulation 102 2000 1748 1754
62. H. Ito, Y. Ouchi, Y. Ohashi A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly the Pravastatin Anti-atherosclerosis Trial in the Elderly (PATE) J Atheroscler Thromb 8 2001 33 44
63. V. Athyros, A. Papageorgiou, B. Mercouris Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvstatin and Coronary-heart-disease Evaluation (GREACE) Study Curr Med Res Opin 18 2002 220 228
64. P. Serruys, P. deFeyter, C. Macaya Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention a randomized controlled trial JAMA 287 2002 3215 3222
65. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) JAMA 288 2002 2998 3007
66. J.A. de Lemos, M.A. Blazing, S.D. Wiviott Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes phase Z of the A to Z Trial JAMA 292 2004 1307 1316
67. M.R. Law, N.J. Wald, S.G. Thompson By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 308 1994 367 372
68. F.M. Sacks, M.A. Pfeffer, L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
69. J. Shepherd, G. Blauw, M. Murphy Pravastatin in elderly individuals at risk of vascular disease (PROSPER) a randomised controlled trial Lancet 360 2002 1623 1630
70. J. Plehn, B. Davis, F. Sacks Reduction of stroke incidence after myocardial infarction with pravastatin the Cholesterol and Recurrent Events study Circulation 99 1999 216 223
71. H. White, J. Simes, N. Anderson Pravastatin therapy and the risk of stroke N Engl J Med 343 2000 317 326
72. Heart Protection Study Collaborative Group Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk complications Lancet 363 2004 757 767
73. M. Aikawa, E. Rabkin, Y. Okada Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma a potential mechanism of lesion stabilization Circulation 97 1998 2433 2444
74. E.M. Balk, J. Lau, L.C. Goudas Effects of statins on nonlipid serum markers associated with cardiovascular disease a systematic review Ann Intern Med 139 2003 670 682
75. R. Paoletti, A.M. Gotto Jr., D.P. Hajjar Inflammation in atherosclerosis and implications for therapy Circulation 109 Suppl 1 2004 III20 III26
76. S.E. Nissen, E.M. Tuzcu, P. Schoenhagen Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease N Engl J Med 352 2005 29 38
77. P.M. Ridker, C.P. Cannon, D. Morrow C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
78. M.R. Ehrenstein, E.C. Jury, C. Mauri Statins for atherosclerosis - as good as it gets? N Engl J Med 352 2005 73 75
79. P. Bogaty, J.M. Brophy, L. Boyer Fluctuating inflammatory markers in patients with stable ischemic heart disease Arch Intern Med 165 2005 221 226
80. R. Corti, V. Fuster, Z.A. Fayad Lipid lowering by simvastatin induces regression of human atherosclerotic lesions two years' follow-up by high-resolution noninvasive magnetic resonance imaging Circulation 106 2002 2884 2887
81. S.E. Nissen, E.M. Tuzcu, P. Schoenhagen Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis a randomized controlled trial JAMA 291 2004 1071 1080
82. G. Schwartz, A. Olsson, M. Ezekowitz Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial JAMA 285 2001 1711 1718
83. S. Okazaki, T. Yokoyama, K. Miyauchi Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study Circulation 110 2004 1061 1068
84. J.C. LaRosa, S.M. Grundy, D.D. Waters Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
85. M. MacMahon, C. Kirkpatrick, C. Cummings A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Nutr Metab Cardiovasc Dis 10 2000 195 203
86. T.R. Pedersen, O. Faergeman, J.J.P. Kastelein Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study Am J Cardiol 94 2004 720 724
87. Merck and Co Package insert Physician's Desk Reference ed 59 2005 Thompson PDR Montvale, NJ 2189 2194
88. Prospective Studies Collaboration Cholesterol, diastolic blood pressure, and stroke 13,000 strokes in 450,000 people in 45 prospective cohorts Lancet 346 1995 1647 1653
89. P. Amarenco, A.M. Tonkin Statins for stroke prevention disappointment and hope Circulation 109 Suppl 1 2004 III44 III49
90. M. Law, N. Wald, A. Rudinka Quantifying the effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke systematic review and meta-analysis BMJ 326 2003 1423 1427
91. D.J. Freeman, J. Norrie, N. Sattar Pravastatin and the development of diabetes mellitus evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study Circulation 103 2001 357 362
92. J. Hay, W. Yu, T. Ashraf Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease Pharmacoeconomics 15 1999 47 74
93. S. Bellosta, R. Paoletti, A. Corsini Safety of statins focus on clinical pharmacokinetics and drug interactions Circulation 109 Suppl 1 2004 III50 III57
94. European guidelines on cardiovascular disease prevention in clinical practice Atherosclerosis 171 2003 145 155